Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-060 vs Metalyse in STEMI
NCT05601999Phase 3Completed
- Sponsor
- Generium
- Start
- Sep 2021
- Primary completion
- May 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tenecteplase in ST elevation myocardial infarction (STEMI), sponsored by Generium. Primary endpoint: Frequency of the complete myocardial reperfusion based on the independent assessment of coronary angiography at 24 hours. Started Sep 2021; status: completed.
02
Drugs
tenecteplase
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05601999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601999.